AtaiBeckley rises as experimental pill shows early benefit for social anxiety

AtaiBeckley

26/02/2026 12:12

** Shares of drug developer AtaiBeckley ATAI.O rise 2% to $4.42 premarket

** Co says its experimental R‑MDMA pill, aimed at easing severe fear of social situations, helped patients more than placebo in a mid‑stage study of 71 adults

** Co says patients on EMP‑01, co's experimental formulation of R‑MDMA, improved by 11.85 points more on a standard scale and 49% were rated “much” or “very much” improved vs 15% on placebo

** No serious side effects reported; most reactions were mild or moderate, co says

** Co plans further analysis and more studies before seeking approval

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))